Nelson, E C
Agrawal, A
Heath, A C
Bogdan, R
Sherva, R
Zhang, B
Al-Hasani, R
Bruchas, M R
Chou, Y-L
Demers, C H
Carey, C E
Conley, E D
Fakira, A K
Farrer, L A
Goate, A
Gordon, S
Henders, A K
Hesselbrock, V
Kapoor, M
Lynskey, M T
Madden, P A F
Moron, J A
Rice, J P
Saccone, N L
Schwab, S G
Shand, F L
Todorov, A A
Wallace, L
Wang, T
Wray, N R
Zhou, X
Degenhardt, L
Martin, N G
Hariri, A R
Kranzler, H R
Gelernter, J
Bierut, L J
Clark, D J
Montgomery, G W
Article History
Received: 14 January 2015
Revised: 12 May 2015
Accepted: 16 June 2015
First Online: 4 August 2015
Competing interests
: Although unrelated to the current study, Dr Kranzler has been a consultant or advisory board member for Alkermes, Lilly, Lundbeck, Pfizer and Roche. He is also a member of the American Society of Clinical Psychopharmacology's Alcohol Clinical Trials Initiative, which is supported by Lilly, Lundbeck, Abbott and Pfizer. The remaining authors declare no conflict of interest.